Skip to main content
. 2023 Mar 17;72(6):781–794. doi: 10.2337/db22-0619

Figure 2.

Figure 2

In vitro functional studies of the effect of CXCL1 and neutrophils. A: HRECs treated with a combination of 25 μg recombinant CXCL1 plus 4 μg IL-1α showed significantly decreased resistance compared with cells grown on normal growth medium; cells treated with 4 μg IL-1α alone did not show any significant change in resistance in comparison with untreated cells (control). B: Coculture of HRECs with 250 μg AGE–pretreated human neutrophils of different numbers: 20,000, 100,000, and 200,000 cells showed a significant decrease in the monolayer resistance in comparison with untreated cells (control). Decreased resistance implies increased permeability. C: mRNA expression of adherent junction molecule VE-cadherin was significantly decreased with 25 μg recombinant CXCL1 treatment compared with untreated cells (control). D: mRNA expression of CXCL1 in different retinal cells in treatment with 250 μg AGE–treated HRECs, human retinal pericytes (HRPs), and human retinal astrocytes (HRAs) were significantly increased in comparison with cells grown on respective normal growth medium (control), except microglia. E: mRNA expression of IL-1α in different retinal cells in treatment with 250 μg AGE. HRECs and HRPs were significantly increased in comparison with cells grown on respective normal growth medium (control), except HRAs and microglia. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.